Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 457 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Epilepsy; Seizure Clear all
Terminated Phase 2 Interventional Results available

IVIG Treatment for Refractory Immune-Related Adult Epilepsy

NCT01545518
View directory record Official record
Conditions
Epilepsy, Cryptogenic, Epilepsy, Partial, Seizure Disorder, Autoimmune Diseases, Nervous System, Limbic Encephalitis
Interventions
IVIG
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2014 · Synced Oct 5, 2026, 5:22 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Retraining and Control Therapy (ReACT): Sense of Control and Symptom Expectations as Targets of a Treatment for PNES

NCT05096273
View directory record Official record
Conditions
Convulsion, Non-Epileptic
Interventions
ReACT
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
11 Years to 18 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Recruiting Phase 3 Interventional

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

NCT04715646
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
1 Month and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
2
States / cities
Hawthorne, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Conversion to Monotherapy Study With Keppra XR for Partial Seizures

NCT00419094
View directory record Official record
Conditions
Epilepsy
Interventions
Keppra XR
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
12 Years to 75 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
24
States / cities
Dothan, Alabama • Northport, Alabama • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 5, 2026, 5:22 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures

NCT05288283
View directory record Official record
Conditions
Seizures Associated With EMAS
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 5, 2026, 5:22 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Cenobamate in the Intensive Care Unit

NCT06352723
View directory record Official record
Conditions
Epilepsy, Neurologic Disorder
Interventions
Cenobamate
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Not applicable Interventional Results available

A Taste and Acceptance Study of FruitiVits in Children Aged 4-8 Years Following a Ketogenic Diet.

NCT02229318
View directory record Official record
Conditions
Seizure Disorders
Interventions
FruitiVits
Dietary Supplement
Lead sponsor
Vitaflo International, Ltd
Industry
Eligibility
4 Years to 9 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dexmedetomidine in Seizure Patients

NCT01116700
View directory record Official record
Conditions
Seizure Disorders
Interventions
Dexmedetomidine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 5, 2026, 5:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

NCT05419492
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ETX101
Drug
Lead sponsor
Encoded Therapeutics
Industry
Eligibility
6 Months to 17 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Completed No phase listed Observational

Heart Rate Changes During Normal Activity, Exercise, and Seizures in Subjects With Epilepsy

NCT01214707
View directory record Official record
Conditions
Epilepsy
Interventions
Exercise
Other
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
2
States / cities
Phoenix, Arizona • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

NCT03936777
View directory record Official record
Conditions
Dravet Syndrome, Lennox Gastaut Syndrome, Epileptic Encephalopathy
Interventions
ZX008 (Fenfluramine Hydrochloride)
Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
2 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
26
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

Pediatric Epilepsy Trial in Subjects 1-24 Months

NCT00043875
View directory record Official record
Conditions
Epilepsy
Interventions
lamotrigine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
1 Month to 24 Months
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
34
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870

NCT04241965
View directory record Official record
Conditions
Epilepsy
Interventions
OPC-214870, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ormond Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 3 Interventional

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

NCT05614063
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
XEN1101, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
56
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Not applicable Interventional

Stress Management Intervention for Living With Epilepsy (SMILE)

NCT01444183
View directory record Official record
Conditions
Epilepsy
Interventions
Progressive muscle relaxation, Sham exercise
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
San Francisco, California • The Bronx, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 3 Interventional

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

NCT00141336
View directory record Official record
Conditions
Seizure Disorder, Partial
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
97
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2007 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Not applicable Interventional Results available

Auricular Acupuncture For The Treatment Of Non-Epileptic Seizures

NCT01919307
View directory record Official record
Conditions
Convulsion, Non-Epileptic
Interventions
Auricular acupuncture
Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 5, 2026, 5:22 AM EDT
Not listed No phase listed Observational

Seizure Detection and Warning System for Epilepsy Patients

NCT01874600
View directory record Official record
Conditions
Epilepsy
Interventions
Brain Sentinel Seizure Detection Device and Warning System
Device
Lead sponsor
Brain Sentinel
Other
Eligibility
13 Years to 21 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 5, 2026, 5:22 AM EDT
Not yet recruiting Early Phase 1 Interventional

Cholinergic Enhancement of Theta

NCT07228338
View directory record Official record
Conditions
Epilepsy, Seizures, Cognitive Impairment, Mild, Memory Disorder, Memory Loss
Interventions
COBENFY KarXT (50/20 mg), Control
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Completed No phase listed Observational

Evaluation of StatNet Device for Electroencephalogram (EEG) Recordings

NCT03103425
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 5, 2026, 5:22 AM EDT
Recruiting Phase 3 Interventional

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

NCT05066217
View directory record Official record
Conditions
Lennox Gastaut Syndrome
Interventions
Clemizole HCl, Placebo
Drug
Lead sponsor
Epygenix
Industry
Eligibility
2 Years to 55 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Little Rock, Arkansas • Orange, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Women With Epilepsy: Pregnancy Outcomes and Deliveries

NCT01259310
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Great Neck, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode

NCT01417078
View directory record Official record
Conditions
Epilepsy
Interventions
Diazepam
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Phoenix, Arizona • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Not applicable Interventional

RNS System NAUTILUS Study

NCT05147571
View directory record Official record
Conditions
Epilepsy, Idiopathic Generalized Epilepsy, Generalized Tonic Clonic Seizure
Interventions
Responsive stimulation, Sham stimulation
Device
Lead sponsor
NeuroPace
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 5, 2026, 5:22 AM EDT